论文部分内容阅读
慢性丙型病毒性肝炎(chronic hepatitis C,CHC)是世界范围内最为严重的感染性疾病之一。据世界卫生组织统计,全球丙型肝炎病毒(hepatitis C virus,HCV)的感染率约为3%,估计约1.5亿人感染了HCV[1]。目前,CHC的标准抗病毒治疗方案是聚乙二醇干扰素(pegylated-interferon,Peg-IFN)α联合利巴韦林。随着分子生物学的发展,针对HCV生活周期中病
Chronic hepatitis C (CHC) is one of the most serious infectious diseases in the world. According to the World Health Organization, the global hepatitis C virus (HCV) infection rate is about 3%, an estimated 150 million people infected with HCV [1]. Currently, CHC’s standard antiviral regimen is pegylated-interferon (IFN-α) in combination with ribavirin. With the development of molecular biology, the disease in the HCV life cycle